Endocrine Abstracts

Neuroendocrine tumours are a heterogeneous group of tumours that arise in diverse anatomical locations and vary greatly in behavior and response to treatment. A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a pathogenic process or response to treatment. Biomarkers can be diagnostic, prognostic, predictive or surrogate markers of clinical endpoints. The management of neuroendocrine tumours has changed dramatically with the intro...

Neuroendocrine tumours have a number of different classification and staging systems. I will present the latest of these, which include the latest WHO system with the implications for new entities and how they are diagnosed pathologically and any difficulties that arise from this. There will also be a more general discussion about areas that are difficult for the pathologist and where we can add value to the MDT discussion....

Abstract unavailable....

This talk aims to highlight the different tracers that are commonly used in the multimodality imaging of neuroendocrine tumours. It will look at both SPECT and PET tracers and their role in diagnosis, planning treatments and monitoring therapies using case examples....

Collectively, typical and atypical lung carcinoids are referred to as the well differentiated lung neuroendocrine cancers (pulmonary NETS). Pulmonary NETS account for only 2% of lung malignancies, however, account for 25% of the total NET presentations. The incidence and prevalence of these cancers is growing. Most pulmonary NETs tend to be localised at presentation and, therefore, amenable to surgical resection. Following surgical resection, there is very little evidence base...

There are three distinct types of gastric Neuroendocrine tumours using the ENETS classification system. Type 1 gastric NETs are most common, accounting for 55–70% of all gastric NETs. Epidemiology studies have suggested an increasing incidence of gastric NETs. Generally type 1 gastric NETs are multifocal in nature and arise in a background of chronic atrophic gastritis. Type 1 Gastric NETs arise from histamine secreting ECL cells, hypergastrinaemia due to excess gastrin r...

Hypoglycaemia due to insulinoma, whether the tumour is advanced or not at the time of diagnosis may be difficult to treat. Profound and recurrent hypoglycaemia may be an important clinical problem for the patient, impacting on daily activities, resulting in recurrent admissions or even preventing safe discharge from an inpatient setting. In this talk we will review the options available for treating hypoglycaemia due to insulinoma, considering the strengths and limitations of ...

Abstract unavailable....

Abstract unavailable....

Abstract unavailable....

Tom Armstrong will present evidence to support the role of surgical resection NET liver in the case based discussion detailed above....

Abstract unavailable....

Abstract unavailable....

Abstract unavailable....

A multidisciplinary team is responsible for the management of over 1,200 NET patients per year in our hospital. Tumor board decisions for peptide receptor radiotherapy (PRRT) are based on the Bad Berka Score which takes into account molecular imaging features and clinical aspects. The therapy plan for each patient is individualized. Retrospective analysis was performed in 1048 patients (age 4–85 years) with progressive NETs treated at our center since 2004 using Lu-177 (<...

Abstract unavailable....